Bristol-Myers Squibb Receives FDA’s Approval for Sprycel (dasatinib) + CT in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

 Bristol-Myers Squibb Receives FDA’s Approval for Sprycel (dasatinib) + CT in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Bristol-Myers Squibb Receives FDA’s Approval for Sprycel (dasatinib) + CT in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Shots:
  • The expansion approval is based on the CA180-372 (NCT01460160) P-II study results assessing Sprycel (qd, 60 mg/m @24 mos.) + CT in 78 patients with Ph+ ALLaged 2 to 10 yrs.
  • The P-II CA180-372 study demonstrated as an effective treatment with EFS binary rate 64.1% in patients with newly diagnosed B-cell precursor Ph+ ALL
  • Sprycel (dasatinib)is second-generation tyrosine kinase inhibitor, approved for use in children with one year of age and older with Ph+ (CMLCP)

Click here to read full press release/ article | Ref: Bms | Image: Bull City Lawyer

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post